MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

MC

556.9

-3.33%↓

SANES

6.177

-1.92%↓

BNP

75.4

-1.39%↓

CS.FR

39.95

-0.77%↓

ALV

356.3

+0.06%↑

Search

Bayer AG

Gesloten

SectorFinanciën

21.37 -4.34

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

21.16

Max

22.34

Belangrijke statistieken

By Trading Economics

Inkomsten

3.9B

-328M

Verkoop

1.8B

12B

K/W

Sectorgemiddelde

30.9

22.015

EPS

1.05

Dividendrendement

0.49

Winstmarge

-2.796

Werknemers

90,587

EBITDA

615M

1.7B

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+20.47% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.49%

3.90%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

422M

22B

Vorige openingsprijs

25.71

Vorige sluitingsprijs

21.37

Nieuwssentiment

By Acuity

26%

74%

87 / 542 Rangschikking in Finance

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

Bayer AG Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 mrt 2025, 09:37 UTC

Belangrijke Marktbewegers

Bayer Shares Plunge After U.S. Court Defeat in Roundup Case -- Update

5 mrt 2025, 11:21 UTC

Winsten

Bayer Warns of Lower Earnings as Turnaround Continues -- 2nd Update

5 mrt 2025, 08:45 UTC

Winsten

Bayer Warns of Lower Earnings as Turnaround Continues -- Update

5 mrt 2025, 07:26 UTC

Winsten

Bayer Warns of Lower Earnings as Work Continues on Turnaround

2 apr 2025, 09:27 UTC

Populaire aandelen

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

10 mrt 2025, 08:38 UTC

Marktinformatie

Bayer's Partial Recovery Is in Sight -- Market Talk

5 mrt 2025, 13:39 UTC

Marktinformatie
Winsten

Bayer Guidance Is Mostly Above Barclays's Expectations, But Cash Flow Looks Light -- Market Talk

5 mrt 2025, 13:26 UTC

Marktinformatie

Bayer Investors Will Need Patience Despite Positive Earnings Surprise -- Market Talk

5 mrt 2025, 08:30 UTC

Marktinformatie
Winsten

Bayer's Cash Flow Guidance Looks Soft -- Market Talk

5 mrt 2025, 06:41 UTC

Winsten

Bayer Launches Plan to Boost Profitability at Crop Science

5 mrt 2025, 06:40 UTC

Winsten

Bayer Sees Tangible Steps Toward U.S. Litigation Containment on Horizon This Year

5 mrt 2025, 06:39 UTC

Winsten

Bayer: Pharmaceuticals Division Projected to Return to Sales Growth From 2027, Expand Margins in 2028

5 mrt 2025, 06:39 UTC

Winsten

Bayer Expects to Increase Combined Sales of Nubeqa and Kerendia From EUR2B to More Than EUR2.5B in 2025

5 mrt 2025, 06:36 UTC

Winsten

Bayer Says 2025 to be Pivotal Year For Turnaround, Improved Performance Expected From 2026

5 mrt 2025, 06:35 UTC

Winsten

Bayer Guidance is on a Currency Adjusted Basis

5 mrt 2025, 06:34 UTC

Winsten

Bayer Sees 2025 Free Cash Flow EUR1.5B-EUR2.5B

5 mrt 2025, 06:34 UTC

Winsten

Bayer Sees 2025 Core EPS EUR4.50-EPS EUR5

5 mrt 2025, 06:33 UTC

Winsten

Bayer Sees 2025 EBITDA Before Special Items of EUR9.5B-EUR10B

5 mrt 2025, 06:33 UTC

Winsten

Bayer Sees 2025 Sales EUR45B-EUR47B

5 mrt 2025, 06:32 UTC

Winsten

Bayer Declares Dividend of EUR0.11 Vs EUR0.11

5 mrt 2025, 06:31 UTC

Winsten

Bayer: Analysts Saw 4Q Net Profit at EUR463M

5 mrt 2025, 06:31 UTC

Winsten

Bayer 4Q Net Loss EUR335M

5 mrt 2025, 06:31 UTC

Winsten

Bayer: Analysts Saw 4Q Ebitda Before Special Items at EUR2.27B

5 mrt 2025, 06:31 UTC

Winsten

Bayer 4Q Ebitda Before Special Items EUR2.35B

5 mrt 2025, 06:31 UTC

Winsten

Bayer: Analysts Saw 4Q Sales at EUR11.26B

5 mrt 2025, 06:31 UTC

Winsten

Bayer 4Q Sales EUR11.73B

13 jan 2025, 21:05 UTC

Top Nieuws

Bayer's Head of Pharma Oelrich Expects Business to Return to Growth in 2027

9 jan 2025, 15:06 UTC

Acquisities, Fusies, Overnames

Bayer Didn't Disclose Financial Details

9 jan 2025, 15:05 UTC

Acquisities, Fusies, Overnames

Bayer: Goal Is to Help Decarbonize Transportation Sector With Advancing Innovative Crops

9 jan 2025, 15:05 UTC

Acquisities, Fusies, Overnames

Bayer: Camelina Is Novel Intermediate Oilseed Crop

Peer Vergelijking

Prijswijziging

Bayer AG Prognose

Koersdoel

By TipRanks

20.47% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 26.89 EUR  20.47%

Hoogste 33 EUR

Laagste 22 EUR

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bayer AG - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

10 ratings

1

Buy

9

Hold

0

Sell

Technische score

By Trading Central

21.95 / 22.575Steun & Weerstand

Korte Termijn

Strong Bearish Evidence

Gemiddeld Termijn

Weak Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

87 / 542 Rangschikking in Financiën

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Bayer AG

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment markets nonprescription over-the-counter medicines, medical products, medicated skincare products, nutritional supplements, and self-care solutions in dermatology, nutritional supplements, pain and cardiovascular risk prevention, digestive health, allergy, and cold and cough. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solution, and pest and weed control products, as well as customer service for agriculture. This segment provides breeding, propagation, and production/processing of seeds, including seed dressing. It has a collaboration agreement with MD Anderson Cancer Center to develop oncology drugs; research and license agreement with Dewpoint Therapeutics, Inc. for the development of new treatments for cardiovascular and gynecological diseases; collaboration agreement with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG; research collaboration with Arvinas Inc.; strategic research partnership with University of Oxford to develop novel gynecological therapies; Kyoto University to identify new drugs candidates for the treatment of pulmonary diseases; and collaboration and license agreement with Cytokinetics for the development and commercialization of aficamten. It distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. The company was founded in 1863 and is headquartered in Leverkusen, Germany.